ARUNA BIO INC.

In News

The Emerging Role of Exosome Therapeutics in 2026 - BioInformant

BioInformant - Oct 27, 2025

Exosome Therapeutics Market Size to Hit USD 4,020.75 Thousand by 2034 - Precedence Research

Precedence Research - Oct 06, 2025

Vicarious Surgical Hires Stephen From as CEO - Medical Product Outsourcing

Medical Product Outsourcing - Aug 04, 2025

Aruna Bio secures US patent for exosome-derived neuroinflammation treatment - Healio

Healio - Aug 20, 2024

Robotic surgery heats up with clearances and clinical trials - Modern Healthcare News

Modern Healthcare News - Aug 19, 2025

Vicarious Surgical has a new CEO - MassDevice

MassDevice - Jul 31, 2025

Vicarious Surgical Appoints Stephen From CEO - citybiz

citybiz - Jul 31, 2025

Aruna Bio’s Exosome AB126 Cleared for US Trial in Acute Ischemic Stroke - CGTLive®

CGTLive® - Jan 23, 2024

Mary M. Worthington Obituary April 19, 2025 - McGuire & Davies Funeral Home and Crematory

McGuire & Davies Funeral Home and Crematory - Apr 19, 2025

Medtech firms shuffle execs in 2025 - MedTech Dive

MedTech Dive - Aug 25, 2025

Aruna Bio’s AB126 eased inflammation in ALS mouse model - ALS News Today

ALS News Today - Sep 12, 2023

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication - BioInformant

BioInformant - Apr 06, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment